Ebola

Ebola Virus Disease (EVD)

Ebola virus disease (EVD), also known as Ebola hemorrhagic fever, is a severe and often fatal infectious disease caused by viruses of the Ebolavirus genus within the Filoviridae family. Ebolaviruses are single-stranded RNA (ssRNA) viruses transmitted through direct contact with infected blood, body fluids, or tissues from infected humans or animals. Fruit bats are considered the most likely natural reservoir. 

Since its discovery in 1976, Ebola has caused multiple outbreaks across Africa, ranging from localized epidemics to large-scale public health emergencies. Depending on the viral species and outbreak conditions, case fatality rates can range from approximately 25% to as high as 90%. 

Ebolavirus research often focuses on viral proteins that are relevant for immune recognition, vaccine development, diagnostic assay design, and therapeutic antibody discovery. Peptide-based tools are especially useful for studying antigen-specific T-cell responses and identifying linear immune epitopes.

Four ebolavirus species are known to cause disease in humans: 

• Zaire ebolavirus (EBOV) 
• Sudan ebolavirus (SUDV) 
• Bundibugyo ebolavirus (BDBV) 
• Taï Forest ebolavirus (TAFV) 

All ebolaviruses are classified as WHO Risk Group 4 (RG4) pathogens. 

Ebola Peptide Pools for Key Ebolavirus Strains 

JPT’s Ebola PepMix™ portfolio includes peptide pools for important ebolavirus strains and antigens, including Zaire Ebola GP/Mayinga-76, Bundibugyo ebolavirus GP/Uganda-07, Sudan ebolavirus GP/Uganda-00, and Taï Forest ebolavirus NP. These products support research workflows where scientists need defined synthetic peptides rather than infectious viral material.

Zaire ebolavirus (EBOV)

The Most Studied and Most Lethal Ebola Species 

Zaire ebolavirus was first identified in 1976 during an outbreak in Yambuku, in what is now the Democratic Republic of the Congo (formerly Zaire), near the Ebola River from which the virus derives its name. The Zaire strain is responsible for the largest and deadliest Ebola outbreaks recorded to date, including the 2014–2016 West African epidemic. Historically, Zaire ebolavirus has shown mortality rates ranging from 60–90%, depending on outbreak conditions and healthcare access. 

Today, Zaire ebolavirus represents the best-characterized of all Ebola strains used in peptide-based immune-response research:: 

• Approved vaccines are available: The recombinant vesicular stomatitis virus vaccine (rVSV-ZEBOV / Ervebo®) is currently approved for prevention of Zaire ebolavirus disease and has significantly improved outbreak response capabilities 
• Monoclonal antibody therapies have been developed 
• Established molecular diagnostic assays exist 
• Extensive immunological and epitope data are available 

Bundibugyo ebolavirus (BDBV)

An Emerging Challenge in Ebola Research

Bundibugyo ebolavirus was first identified in 2007 during an outbreak in the Bundibugyo district of western Uganda. Genetic analysis revealed that the virus differed significantly from previously known Ebola species and therefore constituted a new ebolavirus species. 

Additional outbreaks occurred in the Democratic Republic of the Congo in 2012 and renewed attention to Bundibugyo ebolavirus has increased scientific interest in non-Zaire Ebola strains, including vaccine, therapeutic, diagnostic, and immune-monitoring research.

Compared to Zaire ebolavirus, Bundibugyo ebolavirus generally shows lower mortality rates, typically around 25–50%. However, it presents major scientific and clinical challenges: 

• No licensed vaccines are currently available 
• No approved targeted therapeutics exist 
• Limited diagnostic coverage compared to Zaire strains 
• Less immunological characterization data are available 

Bundibugyo Ebola GP peptide pools can support studies of strain-specific and cross-reactive immune responses, especially where standard assays have historically focused more heavily on Zaire ebolavirus. Recent outbreaks have demonstrated how difficult Bundibugyo infections can be to detect and contain, especially when standard diagnostic workflows are optimized primarily for Zaire ebolavirus.

Sudan ebolavirus (SUDV) 

Sudan ebolavirus is another major Ebola-causing virus associated with severe outbreaks in humans. Unlike Zaire ebolavirus, there is currently no broadly licensed vaccine specifically approved for Sudan ebolavirus disease, making Sudan ebolavirus an important focus for vaccine research, immune monitoring, and diagnostic assay development.

Sudan ebolavirus GP peptide pools can be used to study glycoprotein-specific T-cell responses, compare immune recognition across Ebola strains, and support research into strain-specific or pan-ebolavirus vaccine strategies. 

Taï Forest ebolavirus (TAFV) 

Taï Forest ebolavirus has been associated with human infection and remains relevant for comparative ebolavirus research. Although it is much less frequently reported than Zaire, Sudan, or Bundibugyo ebolaviruses, Taï Forest ebolavirus antigens can support broader studies of ebolavirus immune recognition and cross-reactivity. 

Taï Forest ebolavirus NP peptide pools may be useful for studying nucleoprotein-specific immune responses and comparing conserved immune targets across different Ebola strains.

About Ebolavirus Proteins

The Ebola virus genome encodes several proteins relevant for host immune recognition and viral pathogenicity, including: 

• Glycoprotein (GP) 
• Nucleoprotein (NP) 
• VP24 
• VP30 
• VP35 
• VP40 
• RNA-dependent 
• RNA polymerase (L protein)

Peptide Research Applications

As a result of recent outbreaks, there is increasing interest in: